Jean Luc Veyrune - JoVE Visualize

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Ebiomedicine|July 12, 2020

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trialWilliam Camu, Marius Mickunas, Jean-Luc Veyrune, et al.

Annals of the New York Academy of Sciences|May 21, 2024

Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosisHugo Alarcan, Clément Bruno, Patrick Emond, et al.

Brain Communications|August 19, 2021

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.

Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Ebiomedicine|July 12, 2020

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trialWilliam Camu, Marius Mickunas, Jean-Luc Veyrune, et al.

Annals of the New York Academy of Sciences|May 21, 2024

Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosisHugo Alarcan, Clément Bruno, Patrick Emond, et al.

Brain Communications|August 19, 2021

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.

Pageof 4